52 related articles for article (PubMed ID: 9112135)
1. Transmembranous transport of drugs: implications for kinetics and drug action.
Stratmann G; Jarosch A; Sulzbacher A; Schüler R; Kümel G; Woodcock BG
Int J Clin Pharmacol Ther; 1997 Apr; 35(4):151-4. PubMed ID: 9112135
[No Abstract] [Full Text] [Related]
2. Modulation of vincristine cytotoxicity by dexverapamil in sensitive and resistant HL-60 cell lines as a function of extracellular protein binding.
Stratmann G; Harder S; Hölzer D; Hofmann WK; Ottmann OG; Woodcock BG
Int J Clin Pharmacol Ther; 1998 Feb; 36(2):103-6. PubMed ID: 9520158
[No Abstract] [Full Text] [Related]
3. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells.
Breier A; Drobná Z; Barancík M
Neoplasma; 1998; 45(4):248-53. PubMed ID: 9890669
[TBL] [Abstract][Full Text] [Related]
4. Selective modulation of P-glycoprotein-mediated drug resistance.
Bebawy M; Morris MB; Roufogalis BD
Br J Cancer; 2001 Dec; 85(12):1998-2003. PubMed ID: 11747345
[TBL] [Abstract][Full Text] [Related]
5. Cell membrane perturbations and vincristine transport in sensitive and resistant HL-60 cell lines.
Zichner S; Zimmer G; Woodcock BG
Int J Clin Pharmacol Ther; 1998 Feb; 36(2):99-102. PubMed ID: 9520157
[No Abstract] [Full Text] [Related]
6. [The effect of verapamil on the growth and sensitivity to vincristine of human tumor transplanted into kidney capsule of mice].
Storozhenko IV; Sergeeva NS; Chissov VI; Skotnikova OI
Biull Eksp Biol Med; 1996 Jun; 121(6):681-3. PubMed ID: 9035766
[No Abstract] [Full Text] [Related]
7. Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.
Vilpo J; Koski T; Vilpo L
Haematologica; 2000 Aug; 85(8):806-13. PubMed ID: 10942926
[TBL] [Abstract][Full Text] [Related]
8. Validation of a Caco-2 cell monolayer culture for drug transport studies.
Sulzbacher A; Jarosch A; Schüler R; Acerbi D; Ventura P; Puccini P; Woodcock BG
Int J Clin Pharmacol Ther; 1998 Feb; 36(2):86-9. PubMed ID: 9520153
[No Abstract] [Full Text] [Related]
9. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux.
Hayeshi R; Masimirembwa C; Mukanganyama S; Ungell AL
Eur J Pharm Sci; 2006 Sep; 29(1):70-81. PubMed ID: 16846720
[TBL] [Abstract][Full Text] [Related]
10. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
11. A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein.
Lin JT; Sharma R; Grady JJ; Awasthi S
Drug Metab Dispos; 2001 Feb; 29(2):103-10. PubMed ID: 11159798
[TBL] [Abstract][Full Text] [Related]
12. Expression of P-glycoprotein in L1210 cells is linked with rise in sensitivity to Ca2+.
Sulová Z; Orlický J; Fiala R; Dovinová I; Uhrík B; Seres M; Gibalová L; Breier A
Biochem Biophys Res Commun; 2005 Sep; 335(3):777-84. PubMed ID: 16098480
[TBL] [Abstract][Full Text] [Related]
13. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia.
Stephens RH; O'Neill CA; Warhurst A; Carlson GL; Rowland M; Warhurst G
J Pharmacol Exp Ther; 2001 Feb; 296(2):584-91. PubMed ID: 11160647
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance and P-glycoprotein expression in endothelial cells of newly formed capillaries induced by tumors.
Iwahana M; Utoguchi N; Mayumi T; Goryo M; Okada K
Anticancer Res; 1998; 18(4C):2977-80. PubMed ID: 9713495
[TBL] [Abstract][Full Text] [Related]
15. Transport of doxorubicin in mast cell granules and the effect of the calcium antagonist verapamil.
Candussio L; Decorti G; Crivellato E; Rosati AM; Traversa U; Klugmann FB
Anticancer Res; 1999; 19(2A):1101-8. PubMed ID: 10368660
[TBL] [Abstract][Full Text] [Related]
16. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
Panchagnula R; Bansal T; Varma MV; Kaul CL
Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
[TBL] [Abstract][Full Text] [Related]
17. Role of xenobiotic efflux transporters in resistance to vincristine.
Huang RS; Murry DJ; Foster DR
Biomed Pharmacother; 2008 Feb; 62(2):59-64. PubMed ID: 17583464
[TBL] [Abstract][Full Text] [Related]
18. Development of an automated 7-day 96-well Caco-2 cell culture model.
Galkin A; Pakkanen J; Vuorela P
Pharmazie; 2008 Jun; 63(6):464-9. PubMed ID: 18604991
[TBL] [Abstract][Full Text] [Related]
19. Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects.
Depeille P; Cuq P; Mary S; Passagne I; Evrard A; Cupissol D; Vian L
Mol Pharmacol; 2004 Apr; 65(4):897-905. PubMed ID: 15044619
[TBL] [Abstract][Full Text] [Related]
20. Pumping of drugs by P-glycoprotein: a two-step process?
Litman T; Skovsgaard T; Stein WD
J Pharmacol Exp Ther; 2003 Dec; 307(3):846-53. PubMed ID: 14534356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
